Personalized therapy in SCLC: Promises and challenges
In the third and final podcast on extensive-stage SCLC, the experts discuss ongoing trials, as well as potential predictive biomarkers of response, and the problem of tumor plasticity.
14 Joulu 20229min
Second-line and salvage treatments for metastatic urothelial cancer
In this final episode of our podcast exploring the role of immunotherapy in advanced urothelial cancer, Dr Tom Powles and Dr Aristotelis Bamias discuss the treatment options for patients after first-l...
9 Joulu 202210min
Locally advanced disease
In this second podcast, Dr Tom Powles and Dr Aristotelis Bamias discuss the role of immunotherapy in the neoadjuvant or adjuvant setting for patients with locally advanced disease, based on the latest...
9 Joulu 202213min
First-line treatment of advanced metastatic urothelial cancer
In the first of three podcasts exploring the role of immunotherapy in advanced urothelial cancer, genitourinary cancer experts Dr Tom Powles and Dr Aristotelis Bamias discuss the latest evidence-based...
9 Joulu 202214min
Targeting KRAS G12C Mutations
In this episode, the experts assess the latest data on targeted therapy for KRAS G12C-mutated NSCLC, including the first phase III data on targeted therapy. Hear expert opinions of how these results m...
2 Loka 202211min
Targeting Rare Molecular Drivers
Recent advances in genomic profiling technology have led to the identification of several rare actionable alterations in advanced NSCLC; targeted therapies for many of these molecular NSCLC subtypes a...
1 Loka 202217min
Detection of Osimertinib Resistance and Targeting MET Amplification
In this episode, the experts discuss the latest insights on osimertinib resistance in EGFR-mutated NSCLC and promising new data on targeting MET amplification, one of the most common acquired resistan...
30 Syys 202216min
Targeted Therapy in Early-Stage EGFR-Mutated NSCLC
In this episode, lung cancer experts discuss the treatment approach for patients with early-stage, resectable NSCLC who harbor EGFR sensitizing mutations. Listen to the latest clinical trial data on ...
29 Syys 202210min
